Protein kinase C h (PKCh) is involved in signaling downstream of the T cell antigen receptor (TCR) and is important for shaping effector T cell functions and inflammatory disease development. Acquisition of Th1-like effector features by Th17 cells has been linked to increased pathogenic potential. However, the molecular mechanisms underlying Th17/Th1 phenotypic instability remain largely unknown. In the current study, we address the role of PKCh in differentiation and function of Th17 cells by using genetic knock-out mice. Implementing in vitro (polarizing T cell cultures) and in vivo (experimental autoimmune encephalomyelitis model, EAE) techniques, we demonstrated that PKCh-deficient CD4 + T cells show normal Th17 marker gene expression (interleukin 17A/F, RORct), accompanied by enhanced production of the Th1-typical markers such as interferon gamma (IFN-c) and transcription factor T-bet. Mechanistically, this phenotype was linked to aberrantly elevated Stat4 mRNA levels in PKCh 2/2 CD4 + T cells during the priming phase of Th17 differentiation. In contrast, transcription of the Stat4 gene was suppressed in Th17-primed wild-type cells. This change in cellular effector phenotype was reflected in vivo by prolonged neurological impairment of PKCh-deficient mice during the course of EAE. Taken together, our data provide genetic evidence that PKCh is critical for stabilizing Th17 cell phenotype by selective suppression of the STAT4/IFN-c/T-bet axis at the onset of differentiation.
Introduction
To provide an effective defense against a variety of infectious agents, naïve CD4 + T cells differentiate into functionally diverse T helper effector subsets (Th1, Th2, Th17, iTreg and others) [1] . However, the T helper phenotype is not absolutely stable and pronounced plasticity between particular lineages exists [2] . This phenomenon is especially remarkable within the Th17 lineage [3] .
Th17 cells serve to eliminate extracellular pathogens but also contribute to autoimmunity [4] . They differentiate in response to TGF-b and interleukin 6 (IL-6) [5] and produce mainly IL-17A/F and IL-22. Moreover, Th17 cells are capable of transformation into IFN-c-producing Th1-like effectors [6] [7] [8] . This functional change depends on repetitive TCR stimulation and IL-12 or IL-23 signaling [8] [9] , it increases the pathogenic potential of T cells and is required for development of proper effector responses in vivo [10] [11] . One of the mechanisms underlying this phenotypic plasticity might be an unstable pattern of epigenetic modifications within the Tbx21 and Ifng loci in Th17 cells [12] . However, the exact molecular events regulating Th17/Th1 phenotype balance are not yet fully characterized.
Protein kinase C h (PKCh) is a well-known component of the immunological synapse (IS) and is essential in the signaling cascades that lead to proper NF-kB, AP-1 and NFAT activation [13] . PKCh deficiency leads to impaired IL-2 production as well as to compromised survival and proliferation of CD4 + T cells [14] . Some of these defects may be overcome by other stimulating factors, such as signals from innate immunity or exogenous IL-2 [15] . Notably, PKCh-deficient mice are able to mount relatively normal Th1, but not Th2-type immune responses [16] [17] . Due to its relevance in T cell activation and effector cell functions, PKCh is considered as an attractive molecular drug target in inflammatory diseases [18] . Th17 cells are causative for certain autoimmune disorders, so in this context it is important to understand the exact contribution of PKCh to the functionality of this potentially pathogenic T helper subset.
In the current study, we investigated the role of PKCh in differentiation and function of Th17 CD4
+ cells by using PKChdeficient mice [14] . While the expression of Th17 marker genes under Th17-promoting conditions (in vivo and in vitro) was unaffected by the absence of PKCh, increased expression of the Th1-related markers, interferon gamma (IFN-c) and T-bet, was observed. This cellular phenotypic change correlated with differences in experimental autoimmune encephalomyelitis (EAE) progression. At the molecular level, Th17 phenotypic instability could be linked to delayed Stat4 transcriptional suppression during the early Th17 priming of PKCh 2/2 CD4 + T cells.
Materials and Methods

Ethics Statement
All of the mice were maintained under Specific Pathogen Free (SPF) conditions. All of the experiments complied with the Austrian Animal Welfare Law and Animal Experimental Act (BGBI. Nr.501/1988 and BGBI. Nr. 114/2012) and were approved by the Committee of the Animal Care of the Austrian Federal Ministry of Science and Research. We put efforts to minimize animals' stress and suffering by performing the immunizing injections under anesthesia and controlling animal health status regularly. At the end of experiments, animals were sacrificed by cervical dislocation.
Mice
PKCh 2/2 mice have been described previously [14] . PKCh
mice were backcrossed to a 129/Sv background and used for the experiments at age of 6-12 weeks. Wild-type 129/Sv mice were used as controls.
Experimental Autoimmune Encephalomyelitis (EAE)
EAE was induced and scored as described previously [19] , with modifications. Briefly, 6-12-week-old female mice were immunized at the hind flank by injecting 250 mg of Myelin Oligodendrocyte Glycoprotein peptide (MOG , NeoSystems, Strasbourg, France) emulsified in 100 ml of incomplete Freund's adjuvant (IFA, Thermo Fischer Scientific, Waltham, Massachusetts, USA) supplemented with 5 mg/ml Mycobacterium tuberculosis H37Ra (Difco Laboratories, Franklin Lakes, New Jersey, USA). 250 ng of pertussis Toxin (Sigma Aldrich, St. Louis, Missouri, USA) in 100 ml of PBS were injected intraperitoneally on the day of immunization and 48 h thereafter. The mice were examined daily for disease symptoms, and disease severity was graded according to the following scoring system: 0 -no symptoms; 0,5 -distal weak or spastic tail; 1 -complete limp tail; 1,5 -limp tail and hind limb weakness; 2 -unilateral partial hind limb paralysis, 2,5 -bilateral partial hind limb paralysis, 3 -complete bilateral hind limb paralysis; 3,5 -complete hind limb and unilateral partial forelimb paralysis: 4 -total paralysis or death. Mice were supposed to be immediately sacrificed when reaching the score 4. However, none of the animals reached this score during our experiments.
Isolation of Mononuclear Cell (MNC) Infiltrates from the Central Nervous System
Mononuclear cells (MNCs) infiltrating the nervous system were isolated as described previously [19] . Briefly, brains and spinal cords were taken at onset of the disease symptoms (day 11 after immunization) and washed in PBS. Tissues were cut into pieces and digested with collagenase D (2.5 mg/ml, Roche Diagnostics, Basel, Switzerland) and DNase (1 mg/ml, Sigma Aldrich, St. Louis, Missouri, USA) at 37uC for 45 min. The digested material was passed through a 70mm cell strainer and fractionated by Percoll (GE Healthcare, Little Chalfont, United Kingdom) density gradient (70%/30%) centrifugation. MNCs were collected from interphase, washed with PBS, stained directly for FACS analysis or subjected to re-stimulation with phorbol 12,13-dibutyrate (PDBu)/ ionomycin for intracellular staining of cytokine. To analyze MOGspecific T cell responses, splenocytes and lymph node cells, isolated at onset of the disease, were cultured for 3 days in the presence of MOG peptide (25 mg/ml) in IMDM medium supplemented with FCS and glutamine.
In Vitro Cell Culture and Differentiation
Naïve CD4
+ T cells were sorted from spleen and lymph nodes using the MACS CD4 + CD62L + T Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were cultured in supplemented IMDM medium in the presence of 5 mg/ml platecoated anti-CD3 (produced in house) and 1 mg/ml soluble anti-CD28 antibodies (BD Bioscience, San Jose, California USA).The following conditions were used: Th0 -no further cytokines or antibodies; Th17 -TGF-b [ 
Flow Cytometric Analysis
To stain for transcription factors, cells were fixed and permeabilized using Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, California, USA), according to the manufacturer's instructions. For intracellular flow cytometric (ICF) staining of cytokines cells were re-stimulated for 4 h with phorbol 12,13-dibutyrate (PDBu)/ionomycin (50 ng/ml and 500 ng/ml, respectively) in the presence of Golgi Stop (BD Bioscience San Jose, California USA). Thereafter, the cells were washed, stained for surface antigens and subsequently fixed and permeabilized using the BD Cytofix/Cytoperm Kit (BD Biosciences). Data were acquired on a FACSCalibur instrument (BD Biosciences) and analyzed with FlowLogic software (eBioscience). The following antibodies were used: PE-Cy7-or FITC-conjugated anti-CD4 (RM. [4] [5] , PE-conjugated anti-IL-17A (TC11-18H10), and APCor PE-Cy7-conjugated anti-IFN-c (XMG1.2) from BD Pharmingen; PE-conjugated anti-T-bet (4-B10) and APC-conjugated antiRORct (AFKJS-9) from eBioscience.
Quantitative Real-Time PCR (qRT-PCR)
RNA was isolated using RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturer's instructions. cDNA was synthesized using Omniscript Kit (Qiagen) and oligo-dT primers (Promega, Fitschburg, Wisconsin, USA) and qRT-PCR reactions were conducted using TaqMan technology (reagents were purchased from Life Technologies; Applied Biosystem, Foster City, California, USA). The reactions were run on 7500 FAST and ABI PRIM 7000 instruments (Life Technologies). TATA-Binding Protein (TBP) was used as reference gene.
SDS-PAGE and Western Blot Analysis
Cells were harvested and resuspended in ice-cold lysis buffer (5 mM NaP 2 P, 5 mM NaF, 5 mM EDTA, 50 mM NaCl, 50 mM Tris [pH 7.3], 2% Nonidet P-40 and 50 mg/ml each of aprotinin and leupeptin). After 20 min incubation on ice, lysates were centrifuged (15,0006g, 15 min, 4uC) and supernatants were used for SDS gel electrophoresis (4-12% NuPAGE gels; NOVEX, Life Technologies, Carlsbad, California, USA). Thereafter, proteins were transferred to a PVDF membrane (Immobilion-P, Millipore, Billerica, Massachusetts, USA 
Statistical Analysis
Depending on the structure of data, obtained mean values were analyzed for statistical significance using either an unpaired Student's t-test or a grouped, one-or two-way ANOVA with the Bonferroni post hoc test. Significant differences are indicated in the graphs as follows:
* p,0.05, ** p,0.01 and *** p,0.001. Graphs present mean values with standard error of the mean (SEM) as error bars.
Results
PKCh
2/2 CD4 + T Lymphocytes Differentiate In Vitro into Th17 Cells with Normal Th17, but Enhanced Th1 Features
To address the role of PKCh in Th17 differentiation, naïve CD4 + T cells from PKCh-proficient and -deficient mice were polarized under Th17-promoting conditions in vitro. The polarized Th17 cells were then analyzed for production of lineage-specific cytokines and transcription factors by flow cytometry, qRT-PCR and Bioplex System at day 4 of culture. We observed comparable expression of the major Th17 marker genes (IL-17A and RORct) by PKCh-deficient and wild-type (WT) CD4 + T cells ( Fig. 1A and B). Furthermore, similar expression of other Th17-related cytokines (IL-17F, IL-21, IL-22, and TGF-b), and of transcription factor IRF4, was revealed in both genotypes (Fig. S1A) . Total protein levels, as well as IL-6-induced phosphorylation of STAT3, were also unaffected (Fig. S1B) . Interestingly, we detected significantly increased frequency of cells producing IFN-c in PKCh2/2 Th17 cell cultures. In line with this, higher IFN-c concentration was determined in the supernatants of those cultures ( Fig. 1A and B) . Similarly, the major Th1 transcription factor, Tbet, was increased in PKCh2/2 Th17 CD4+ cells on protein as well as on mRNA level ( Fig. 1A and C). We detected severely impaired production of IL-2 by PKCh2/2 Th17 CD4+ cells, what is in accordance with previous observations showing general impairment of expression of this cytokine under PKCh deficiency [14] (Fig. S1C ). Taken together, PKCh2/2 CD4+ T cells, albeit able to develop typical Th17 features, displayed an enhanced Th1-like phenotype under Th17-polarizing conditions in vitro.
2/2 Th17 CD4 + Cells Are More Potent INF-c Producers In Vivo Resulting in a Prolonged EAEPathogenesis
To investigate Th17 response in an in vivo setting, we analyzed PKCh-deficient and wild-type mice for the development of murine experimental autoimmune encephalomyelitis (EAE), a commonly used model for multiple sclerosis (MS). After immunization with myelin oligodendrocyte glycoprotein peptide (MOG 35-55 peptide), mice of both genotypes developed first signs of disease at day 11-12 ( Fig. 2A) . Furthermore, disease incidence was comparable (WT -21 of 26, PKCh2/2 223 of 24), and no difference in the mean maximal symptoms score was observed (WT -2,4; PKCh2/22 2,07; p = 0,312). However, a significant difference in the overall disease progression was apparent. Namely, the phase of severe paralysis was delayed as well as prolonged in PKCh (Fig. 2B and C) . In agreement with this, ex vivo MOG-specific stimulation of CD4 + cells isolated from lymph nodes and spleens of PKCh 2/2 animals suffering from EAE resulted in increased IFN-c and T-bet frequencies, when compared to wild-type controls (Fig. 2D) . Reminiscent to the in vitro situation (Fig. 1) , wild-type and PKC-deficient CD4
+ cells contained comparable percentage of IL-17A-producing cells (Fig. 2D ). In summary, we confirmed the Th1-skewed phenotype of the PKCh 2/2 Th17 CD4 + cells in vivo and, furthermore, could link this to differences in the EAE disease progression between wild-type and PKCh 2/2 animals.
Enhanced IFN-c and T-Bet Expression in PKCh 2/2 CD4 + T Cells Is Limited to the Th17 Subset
Considering the observed Th1-skewed phenotype of PKCh
2/2
Th17 cells, we determined the expression of IFN-c and T-bet under conditions favorable to their production. When naïve CD4 + T cells were cultured under neutral (Th0) or Th1-promoting conditions, no significant differences in the expression of IFN-c or T-bet (neither on protein nor on mRNA level) between wild-type and PKCh 2/2 T lymphocytes were observed ( Fig. 3A and B) .
Early Up-Regulation of IFN-c Production by PKCh
2/2
Th17 CD4 + Cells Is Independent of IL-23
Based on the fact that Th17 cells are able to gain the ability to produce IFN-c [8] , we decided to analyze the kinetic of IFN-c expression during Th17 polarizing culture. In PKCh 2/2 Th17 cultures a larger, stable fraction of IFN-c-secreting cells was present from as early as day 1 of differentiation, while IFN-cproducers were scarce in wild-type cultures. However, in cultures of both genotypes, we did not detect any time-dependent increase of IFN-c + cells frequencies (Fig 4A) . Similarly, IFN-c mRNA was rapidly up-regulated only in PKCh 2/2 Th17-primed CD4 + cells (Fig. 4B) . The increased expression of IFN-c was accompanied by enhanced phosphorylation of STAT1, the major IFN-c signaling mediator (Fig. 4C) . In contrast to IFN-c, T-bet protein and mRNA levels initially increased in the cells of both genotypes, most likely in response to the TCR stimulation [20] (Fig. 4A and  B) . However, following day 3 of culture, T-bet expression decreased in wild-type Th17 CD4
+ cells, but stayed high in PKCh 2/2 cells (see Fig. 1A and C). This difference disappeared when no anti-IFN-c neutralizing antibodies were added to the Th17 differentiation medium (Fig. 4D) , suggesting that low secretion of IFN-c by wild-type Th17 cells is sufficient to support T-bet expression in the absence of neutralizing anti-IFN-c antibodies. Thus, elevated IFN-c signaling in PKCh 2/2 cells may contribute to the higher T-bet protein levels observed from day 4 on [21] .
IL-23 supports expansion of established Th17 cells, but it may also promote their Th1-directed phenotype transformation [7] [8] .
To test whether the Th-1-skewed phenotype of PKCh 2/2 Th17 CD4 + cells may be caused by an altered sensitivity to IL-23, we conducted in vitro differentiation of naïve CD4 + T cells with and without the addition of IL-23. These experiments revealed that, as observed previously, PKCh 2/2 Th17 CD4 + cells produced IL-17A at equal frequencies as wild-type cells, but expressed more IFN-c and T-bet, irrespective of the addition of IL-23 (Fig. 5A) . Since, due to the inducible and time-delayed expression of its receptor, IL-23 acts only on differentiated Th17 cells [22] , polarized Th17 cells were re-stimulated with IL-23 alone or with combination of TGF-b and IL-6. Also under these regimens, the frequencies of IFN-c-producing cells were equally high in PKChdeficient, but low in wild-type cell cultures (Fig. S3A) . Taken together, these data show that PKCh 2/2 Th17 CD4 + cells are able to produce increased amounts of IFN-c constantly and independently of IL-23 receptor signaling.
PKCh
2/2 CD4 + T Cells Remain Sensitive to TGF-bMediated Inhibition
Because the enhanced expression of Th1 marker genes in PKCh 2/2 CD4 + cells is limited to the Th17 subset, we considered additional Th17-specific regulatory mechanisms. TGF-b promotes Th17 differentiation in combination with IL-6 [5] and is a known 
STAT4 Expression Is Differently Regulated in Wild-Type and PKCh 2/2 CD4 + T Cells during Th17 Priming
So far, our results showed that increased IFN-c production by PKCh 2/2 Th17 CD4 + cells precedes T-bet up-regulation. Based on this observation, we focused our next analyses on factors which are known to directly promote IFN-c expression. The most obvious candidate is STAT4, which canonically mediates IL-12-induced IFN-c expression [20] . Thus, we determined phosphorylation of STAT4 at two different time points (45 min and 20 h) of Th17 differentiation, as well as under diverse stimulatory conditions. Short-term treatment (45 min) with IL-6 resulted in strong STAT4 phosphorylation both in wild-type and PKCh
2/2
CD4
+ T cells (Fig. 6A) . Importantly, this phosphorylation was transient under Th17-promoting conditions, as it was barely detectable after 20 hours of Th17-polarizing culture. Surprisingly, + cells. C) Quantification of cytokine-producing CD4 + T cell. Graphs depict results from two independent experiments with n = 3 per genotype for brain samples and from one experiment with n = 3 per genotype for SC and LNs. D) Cells from the lymph nodes and spleens were isolated at onset of the disease (day 11 after EAE-inducing immunisation). Cells were cultured in vitro in the presence of MOG at this time point, PKCh 2/2 CD4 + T cells showed higher expression level of total STAT4 protein, accompanied by an increase in the amount of its phosphorylated form, than wild-type cells ( Fig. 6A and B) . Of note, this differential pattern of regulation was observed only under Th17-promoting, and not under neutral or Th1-promoting conditions.
Based on the protein expression kinetics (Fig. S4A) , it seems that wild-type CD4 + T cells down-regulate STAT4 expression almost immediately after the initiation of Th17 differentiation (1-9 h). This down-regulation is much less pronounced under PKCh deficiency. Consequently, the biggest difference in STAT4 protein levels between wild-type and PKCh 2/2 cells is observed after 20 hours of Th17 culture and disappears at later time points (Fig.  S4A) . Although IL-23 is known to promote the phosphorylation of numerous STAT proteins, including STAT4 [26] , the presence of this cytokine had no effect on the STAT4 dynamics in our experiments (Fig. 6B) .
To determine which factors in the Th17-differentiation medium were responsible for STAT4 down-regulation, we activated naïve CD4 + T cells with anti-CD3/anti-CD28 antibodies and cultured them in the presence of IL-6 and TGF-b, separately or in combination. After 20 hours, we observed that TGF-b was required to induce STAT4 down-regulation, but the differences between the genotypes were visible only in the presence of both cytokines (Fig. S4B) .
Since STAT4 protein expression can be regulated by both transcriptional regulation [27] [28] and protein degradation [29] , we wanted to investigate which of these processes contributes to the differences observed between wild-type and PKCh 2/2 CD4 + T cells during Th17 priming. PKCh is known to be involved in the regulation of numerous transcription factors [13] , therefore, we first investigated Stat4 mRNA levels within the initial hours of Th17 polarization. Stat4 mRNA was rapidly down-regulated in wild-type CD4 + T cells, while this process was delayed in the absence of PKCh (Fig. 6C ). These differences in mRNA kinetic corresponded to higher STAT4 protein levels in PKCh 2/2 Th17 CD4 + cells. Of note, also PKCh mRNA expression was found to be down-regulated early during Th17 differentiation (Fig. 6D) . This phenomenon, already described in the literature [30] , was observed by us also under different stimulation conditions (not shown). This observation goes in line with the assumption that PKCh works as a regulatory factor during the early phase of phenotype determination and its activity declines once the effective Stat4 suppression is established.
Discussion
The current study identified a new and entirely unexpected role of PKCh in regulating the phenotype of Th17 cells subset. In vivo and in vitro derived PKCh 2/2 Th17 CD4 + cells, although able to express normal amounts of subset-specific genes, are phenotypically unstable and show a strong tendency to gain Th1-like features. This may affect their physiologic functionality, as well as pathogenic potential.
Our results are in contrast to previous investigations, which have suggested a permissive role of PKCh in the development of Th17 responses and autoimmunity [31] [32] [33] . According to these authors, PKCh is required for effective IL-17 expression, STAT3 activation and susceptibility to EAE development. Of note, we reproducibly did not observe any of those phenomena. It should be underlined, however, that the cited results were obtained with a transgenic mouse strain generated with a different knockout strategy than the one used in our laboratory [34] . Distinct phenotypic and biochemical differences between these two knockout models have been previously reported [14] . Moreover, the different genetic background of the mice (C57BL/6 versus 129/sv used in our study) may also contribute to the observed discrepancy. In a couple of disease models, 129/Sv mice show responses different from the C57BL/6 strain [35] [36] . For example, the 129/Sv strain is described to be less susceptible to EAE induction and to mount stronger IFN-c responses against pathogenic insults [37] . Supporting this hypothesis, one group reported previously that the effect of PKCh deficiency was dependent on the genetic background of the mouse strain [38] . Above that, it should to be taken into account that many effects of PKCh deficiency might be overcome by additional stimulation or partially compensated by redundant PKC isoforms [15] [39] .
General progression of autoimmune conditions is regulated by the counter-play between different Th subsets and cytokines. In example, the pathogenesis of EAE is driven by both Th17 and Th1 mechanisms, and changes in the balance of these two T helper subsets result in alterations in the disease progression [40] . IFN-c has been shown to play a protective role in acute inflammatory processes, especially within the nervous system [41] , and the genetic ablation of IFN-c signaling in mice leads to an exacerbated form of EAE [42] . On the other hand, the same cytokine plays a role in chronic and late inflammatory responses [6] [7] . In addition to the requirement of T-bet for Th17 cellsinduced encephalitogenicity [43] , elevated IFN-c production in PKCh-deficient mice may ameliorate disease severity during acute stages after immunization, but also may promote an elongation of sever disease phase, as observed in our experimental system.
Here, we examined the molecular basis of phenotypic instability of PKCh 2/2 Th17 CD4 + cells. We conclude that the observed Th1-directed skewing of the phenotype is not due to the ''late developmental plasticity''. Instead, it might be a consequence of altered cellular signaling during an early Th17-priming phase, which then results in an incomplete suppression of Th1-typical genes. This hypothesis is based on the increased IFN-c expression observed at the beginning of Th17 polarization. Although restricted to the Th17 subset, the enhanced expression of IFN-c by PKCh 2/2 CD4 + cells was not caused by an altered TGF-b responsiveness. We propose that PKCh-dependent regulation of STAT4 influences IFN-c production under Th17-promoting conditions. STAT4 is most widely known as an IL-12-activated Th1 inducer [20] . Moreover, it plays also more subtle roles in determination and function of other T helper subsets; for instance, STAT4 has been shown to control the late IL-23-dependent expression of IFN-c in Th17 cells [44] . Similarly, presence of STAT4 and T-bet is required to permit plasticity of memory CD4 + T cells -namely, to enable IFN-c expression in Th2-differentiated lymphocytes [45] . We observed prominent differences between STAT4 regulation in PKCh 2/2 and wild-type CD4 + T cells in the presence of Th17-promoting cytokines. Both total protein and phosphorylation levels of STAT4 were higher in PKCh 2/2 CD4 + T cells during the Th17 priming, what corresponds with the observed enhancement of IFN-c expression.
The protein level of STAT4 is the combined consequence of active transcription [29] and protein degradation, the later being mainly induced by a strong and persistent stimulation [46] . Since numerous reports have postulated that transcriptional suppression is the main mechanism of STAT4 down-regulation [27] [28] [47], we focused on investigating Stat4 mRNA transcripts. The obtained data correlated well with the observed changes in STAT4 protein levels. As STAT4 mainly influences transcription by providing permissive chromatin modifications [48] [49], its prolonged presence in cells allows continuous IFN-c production. How exactly PKCh influences STAT4 levels remains unknown. However, we postulate that PKCh is involved early during the Th17-priming phase (up to 24 h). This time frame is in agreement with the fact that PKCh is activated immediately after TCR engagement. Moreover, we observed a strong down-regulation of PKCh expression after the Th17 priming, mechanistically explaining its selective role only during this early phase of differentiation. PKCh positively regulates a wide range of transcription factors from the AP-1, NF-kB and NFAT families. Most of these act as transcription activators, but some may have inhibitory properties [50] [51] . However, the regulation of STAT4 by PKCh may also be less direct. One report from human cells showed that PKCh influences the transcription of miRNA clusters [52] and, in turn, controls expression of many other genes. This type of complex regulation may serve as a fine-tuning of a cellular phenotype.
In conclusion, our data are the first to provide experimental evidence that PKCh is an early factor involved in developing a stable Th17 cell phenotype. Mechanistically, it acts as a reprogramming element that suppresses the STAT4/IFN-c/Tbet axis. Thus, PKCh is an essential link between TCR signaling and inhibition of Th1-typical genes during Th17 immunity. STAT4, T-bet and IFN-c are often implicated in autoimmune and inflammatory disorders [41] [43] [53] . Consequently, a new aspect of Th17/Th1 phenotype regulation described here has to be carefully considered in PKCh-targeted immunosuppression therapy regimens. Figure S1 Th17-related genes expression and IL-2 production defect in in vitro differentiated PKCh 
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